Effect of pravastatin treatment on Chlamydia pneumoniae infection, inflammation and serum lipids in NIH/S mice

International Journal of Antimicrobial Agents

Volumn 29, Issue 6, 2007, Pages 741-742

  Tiirola, Terttu ^a   Jauhiainen, Matti ^a   Erkkilä, Leena ^a   Bloigu, Aini ^a   Leinonen, Maija ^a   Haasio, Kristiina ^b   Laitinen, Kirsi ^c   Saikku, Pekka ^d  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b ORION CORPORATION   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; METHOXYFLURANE; PRAVASTATIN; SIMVASTATIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIUM ISOLATION; BLOOD SAMPLING; CHLAMYDOPHILA PNEUMONIAE; DRUG EFFICACY; ENZYME CHEMISTRY; ENZYME IMMUNOASSAY; IMMUNE RESPONSE; INCUBATION TIME; INOCULATION; LETTER; LIPID BLOOD LEVEL; LIPID METABOLISM; LUNG PARENCHYMA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LIPIDS; MICE; MICE, INBRED STRAINS; PRAVASTATIN;

EID: 34248207089     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.02.001     Document Type: Letter

References (8)

1. Leinonen M., and Saikku P. Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2 (2002) 11-17
2. Laurila A., Bloigu A., Näyhä S., et al. Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 17 (1997) 2910-2913
3. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
4. Erkkilä L., Jauhiainen M., Laitinen K., et al. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 49 (2005) 3959-3962
5. Blanco-Colio L.M., Tunon J., Martin-Ventura J.L., et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63 (2003) 12-23
6. Bernot D., Benoliel A.M., Peiretti F., et al. Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha. J Cardiovasc Pharmacol 41 (2003) 316-324
7. Hackstadt T., Scidmore M.A., and Rockey D.D. Lipid metabolism in Chlamydia trachomatis-infected cells: directed trafficking of Golgi-derived sphingolipids to the chlamydial inclusion. Proc Natl Acad Sci USA 92 (1995) 4877-4881
8. Ziegler K., and Stunkel W. Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1139 (1992) 203-209